Search
Sinopharm Achieves Breakthrough Therapy Designation for Fedratinib Tablets
2025-08-07 /
Read about 0 minute
Author：小编
China Biopharmaceutical Co., Ltd. has announced that the Phase III clinical trial of its independently developed fedratinib for the treatment of moderate to severe chronic graft-versus-host disease (cGVHD) has commenced the subject recruitment phase. Fedratinib holds the distinction of being the world's first JAK/ROCK dual small molecule inhibitor to reach the clinical stage. The company has affirmed its commitment to expediting the global clinical development of this groundbreaking drug, aiming to offer a superior treatment option to patients worldwide at the earliest possible opportunity.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
